Search research articles
Contact Us
Filters
Showing results (121-130 of 131) with videos related to
Page
of 14
Sort By:
Cell Death & Disease
|
October 18, 2020
Identification of BCL-XL as highly active survival factor and promising therapeutic target in colorectal cancer
Anna-Lena Scherr, Andreas Mock, Georg Gdynia, et al.
Annals of Surgical Oncology
|
June 19, 2024
Comparing Survival of Perihilar Cholangiocarcinoma After R1 Resection Versus Palliative Chemotherapy for Unresected Localized Disease
Anne-Marleen van Keulen, Stefan Buettner, Pim B Olthof, et al.
Hepatology (Baltimore, Md.)
|
January 12, 2020
Genomic Characterization of Cholangiocarcinoma in Primary Sclerosing Cholangitis Reveals Therapeutic Opportunities
Benjamin Goeppert, Trine Folseraas, Stephanie Roessler, et al.
Nature Reviews. Gastroenterology & Hepatology
|
February 9, 2023
Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevance
Diego F Calvisi, Luke Boulter, Javier Vaquero, et al.
Nature Reviews. Gastroenterology & Hepatology
|
December 10, 2025
Cholangiocarcinoma 2026: status quo, unmet needs and priorities
Jesus M Banales, Pedro M Rodrigues, Silvia Affò, et al.
Neuro-Oncology
|
July 22, 2025
Distinct molecular profile and outcome of oligodendroglioma, IDH-mutant, 1p/19q-codeleted and TERTp-wildtype: a grade 1 oligodendroglioma of young patients?
Filippo Nozzoli, Ramin Rahmanzade, Simone Schmid, et al.
Clinical and Translational Medicine
|
June 15, 2024
Integrative genomic analyses of European intrahepatic cholangiocarcinoma: Novel ROS1 fusion gene and PBX1 as prognostic marker
Patrick S Plum, Timo Hess, Denis Bertrand, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
August 19, 2022
Bcl-x<sub>L</sub> as prognostic marker and potential therapeutic target in cholangiocarcinoma
Paula Hoffmeister-Wittmann, Andreas Mock, Federico Nichetti, et al.
Hepatology (Baltimore, Md.)
|
November 2, 2023
Etiology-independent activation of the LTβ-LTβR-RELB axis drives aggressiveness and predicts poor prognosis in HCC
Anna-Lena Scherr, Luisa Nader, Kaiyu Xu, et al.
Nature
|
February 4, 2026
Activated ATF6α is a hepatic tumour driver restricting immunosurveillance
Xin Li, Cynthia Lebeaupin, Aikaterini Kadianaki, et al.
Page
of 14
Search research articles
Search
Showing results (121-130 of 131) with videos related to
Sort By:
Page
of 14
Cell Death & Disease
|
October 18, 2020
Identification of BCL-XL as highly active survival factor and promising therapeutic target in colorectal cancer
Anna-Lena Scherr, Andreas Mock, Georg Gdynia, et al.
Annals of Surgical Oncology
|
June 19, 2024
Comparing Survival of Perihilar Cholangiocarcinoma After R1 Resection Versus Palliative Chemotherapy for Unresected Localized Disease
Anne-Marleen van Keulen, Stefan Buettner, Pim B Olthof, et al.
Hepatology (Baltimore, Md.)
|
January 12, 2020
Genomic Characterization of Cholangiocarcinoma in Primary Sclerosing Cholangitis Reveals Therapeutic Opportunities
Benjamin Goeppert, Trine Folseraas, Stephanie Roessler, et al.
Nature Reviews. Gastroenterology & Hepatology
|
February 9, 2023
Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevance
Diego F Calvisi, Luke Boulter, Javier Vaquero, et al.
Nature Reviews. Gastroenterology & Hepatology
|
December 10, 2025
Cholangiocarcinoma 2026: status quo, unmet needs and priorities
Jesus M Banales, Pedro M Rodrigues, Silvia Affò, et al.
Neuro-Oncology
|
July 22, 2025
Distinct molecular profile and outcome of oligodendroglioma, IDH-mutant, 1p/19q-codeleted and TERTp-wildtype: a grade 1 oligodendroglioma of young patients?
Filippo Nozzoli, Ramin Rahmanzade, Simone Schmid, et al.
Clinical and Translational Medicine
|
June 15, 2024
Integrative genomic analyses of European intrahepatic cholangiocarcinoma: Novel ROS1 fusion gene and PBX1 as prognostic marker
Patrick S Plum, Timo Hess, Denis Bertrand, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
August 19, 2022
Bcl-x<sub>L</sub> as prognostic marker and potential therapeutic target in cholangiocarcinoma
Paula Hoffmeister-Wittmann, Andreas Mock, Federico Nichetti, et al.
Hepatology (Baltimore, Md.)
|
November 2, 2023
Etiology-independent activation of the LTβ-LTβR-RELB axis drives aggressiveness and predicts poor prognosis in HCC
Anna-Lena Scherr, Luisa Nader, Kaiyu Xu, et al.
Nature
|
February 4, 2026
Activated ATF6α is a hepatic tumour driver restricting immunosurveillance
Xin Li, Cynthia Lebeaupin, Aikaterini Kadianaki, et al.
Page
of 14